Credits Available: 4.75 AMA PRA Category 1 Credit™/ MOC Points

Description: This curriculum examines the latest advancements in antibody-drug conjugate (ADC) therapy for metastatic triple-negative breast cancer (mTNBC) and HER2-low (HER+/HER2-) breast cancer. It provides insights into mechanisms of action, emerging clinical data, and strategies for integrating ADCs into treatment regimens to improve patient outcomes. Expert-led discussions and case-based learning will support clinicians in individualizing therapy and addressing real-world challenges in ADC use.

CME/CE Accreditation Information

If you already have a Gather-ed account, please login

Email:
Password:

Register

Step 1 of 3

This program is intended for:
Target Professions: DO, MD, Nurse Practitioner, Physician Associate/Assistant
Target Specialties: Oncology

Jennie Petruney

Jennie Petruney
AOCNP

Acute oncology certified nurse practitioner in practice taking care of breast cancer patients since 2012. I have worked at both UNC and Duke Cancer Centers with some of the leaders in breast medical oncology nationally. I am the lead APP for the breast medical oncology group at Duke and also the lead APP for breast medical oncology for the Duke Center for Brain and Spine Metastasis